CAMBRIDGE, Mass., Feb. 22 (UPI) -- U.S. biotech corporation Genzyme said Monday activist investor Carl Icahn intends to nominate four directors to its nine-member board.
Genzyme said it would "evaluate the nominees and make a recommendation that is in the best interests of all the company's shareholders," an indication it is attempting to negotiate with Icahn and potentially avoid losing its chief executive officer, Henri Termeer, in a proxy fight for control of the board.